Related Experiment Video
Updated: Aug 15, 2026
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 11, 2013
Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers
L E Rothuizen1, T Buclin, F Spertini
1Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland.
Insights
Comparing interferon-beta (IFN-beta) regimens for immune-mediated diseases reveals administration schedule significantly impacts biological effects. Dividing a weekly dose into three injections enhances immunomodulation compared to once-weekly dosing.
Area of Science:
- Immunology
- Neuroimmunology
- Pharmacology
Background:
- Interferon-beta (IFN-beta) is used for immune-mediated diseases like multiple sclerosis (MS).
- Biological effects of different IFN-beta regimens have not been directly compared.
- Understanding optimal dosing schedules is crucial for therapeutic efficacy.
Purpose of the Study:
- To compare the biological effects of various subcutaneous recombinant IFN beta-1a (Rebif) administration schedules.
- To assess the impact of dosing frequency on cytokine secretion and serum response markers.
- To determine if administration schedule influences in vivo immunomodulation.
Main Methods:
- Randomized, parallel-group, placebo-controlled study involving healthy volunteers.
- Assessment of cytokine production (IL-1beta, IL-6, IFN-gamma, TNF-alpha, TNF-beta, IL-10) from mitogen-stimulated peripheral blood mononuclear cells (PBMCs).
- Measurement of serum markers: beta2-microglobulin, neopterin, and 2-5A-synthetase.
- Volunteers received IFN beta-1a at 22 mcg once weekly (QW), 22 mcg three times weekly, 66 mcg QW, or placebo.
Main Results:
- IFN-beta injections markedly decreased pro-inflammatory cytokine production (IL-1beta, IL-6, IFN-gamma, TNF-alpha, TNF-beta) within 24-48 hours.
- This cytokine reduction showed limited dose-dependency and no tolerance or augmentation over one month.
- Serum beta2-microglobulin, neopterin, and 2-5A-synthetase increases were more sustained.
- The time-integrated immunomodulatory effect was 2-3 times greater when the same weekly dose was divided into three injections.
Conclusions:
- IFN-beta-induced immunomodulation in vivo is highly dependent on the administration schedule.
- Dividing a weekly dose of IFN-beta into multiple injections significantly enhances its immunomodulatory effects compared to less frequent dosing.
- These findings have implications for optimizing IFN-beta therapy in immune-mediated diseases.
Abstract:
Interferon-beta regimens for immune-mediated diseases, such as multiple sclerosis (MS), have not been compared regarding their biological effects. In this randomized, parallel-group, placebo-controlled study, cytokine secretion by mitogen-stimulated PBMCs and serum response markers were assessed in volunteers receiving subcutaneous recombinant IFN beta-1a (Rebif, Ares-Serono) 22 microg once a week (QW), 22 microg three times a week, 66 microg QW, or placebo. The production of IL-1beta, IL-6, IFN-gamma, TNF-alpha and TNF-beta markedly decreased during 24-48 h after each injection, with limited dose-dependency and no evidence of tolerance or effect augmentation over 1 month. IL-10 secretion remained unchanged. The increase in serum beta2-microglobulin, neopterin and 2-5A-synthetase was more sustained. Thus, IFN-beta-induced immunomodulation in vivo strongly depends on the administration schedule, the time-integrated effect being 2-3 times greater when a same weekly dose is divided in three injections.
More Related Videos
09:26In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function
Published on: October 16, 2013
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023